Voya Investment Management LLC Boosts Stock Position in United Therapeutics Corporation $UTHR

Key Points

• Voya Investment Management LLC increased its stake in United Therapeutics Corporation by 15.7%, owning approximately 44,595 shares worth $13,747,000 after buying an additional 6,047 shares in the first quarter.
• Several institutional investors, including Acadian Asset Management and UBS AM, have significantly increased their holdings in United Therapeutics, demonstrating high interest as 94.08% of the stock is owned by such investors.
• Bank of America and HC Wainwright raised their target prices for United Therapeutics, with the average target now at $438.85, reflecting optimistic growth prospects among analysts.

Voya Investment Management LLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 15.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 44,595 shares of the biotechnology company's stock after purchasing an additional 6,047 shares during the period. Voya Investment Management LLC owned approximately 0.10% of United Therapeutics worth $13,747,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of UTHR. Acadian Asset Management LLC lifted its holdings in shares of United Therapeutics by 1,657.8% during the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company's stock worth $55,217,000 after purchasing an additional 169,010 shares during the period. Geneos Wealth Management Inc. lifted its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the period. Intech Investment Management LLC lifted its stake in United Therapeutics by 1.4% during the 1st quarter. Intech Investment Management LLC now owns 30,935 shares of the biotechnology company's stock valued at $9,536,000 after acquiring an additional 442 shares during the period. Capital Impact Advisors LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at $6,508,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of United Therapeutics by 10.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 257,662 shares of the biotechnology company's stock worth $79,429,000 after acquiring an additional 25,289 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Tommy G. Thompson sold 4,560 shares of the business's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $403.36, for a total transaction of $1,839,321.60. Following the completion of the sale, the director owned 8,480 shares of the company's stock, valued at $3,420,492.80. The trade was a 34.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 11,375 shares of the company's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $397.41, for a total transaction of $4,520,538.75. The disclosure for this sale can be found here. Insiders have sold 128,816 shares of company stock worth $45,836,113 in the last 90 days. 10.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on UTHR. Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. Wells Fargo & Company raised their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a report on Wednesday, September 3rd. Morgan Stanley reduced their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, UBS Group boosted their price target on United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a report on Thursday, September 4th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $438.85.

United Therapeutics Trading Down 0.5%

Shares of UTHR stock opened at $403.11 on Tuesday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $436.95. The business's 50 day moving average is $320.79 and its two-hundred day moving average is $307.95. The company has a market capitalization of $18.18 billion, a P/E ratio of 15.73, a P/E/G ratio of 6.17 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the firm earned $5.85 earnings per share. The firm's quarterly revenue was up 11.7% compared to the same quarter last year. On average, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.